Literature DB >> 6363350

Neonatal septic arthritis.

M Dan.   

Abstract

To assess and correlate the microbiology of neonatal septic arthritis with the clinical presentation, we reviewed the records of nine infants with neonatal septic arthritis (NSA) diagnosed at Edmonton hospitals between 1964 and 1981, and evaluated 92 other cases reported in the English literature since 1960. Our analysis revealed that the microbiology of NSA seemed to be dependent on whether it was hospital or community acquired. In the hospital-acquired cases, staphylococci were the predominant isolates (62%), followed by Candida species (17%) and gram-negative enteric bacilli (15%). Community-acquired arthritis was caused most often by streptococci (52%), followed by staphylococci (26%) and gonococci (17%). Since 1970, the relative infrequency of staphylococcal (5%) in favor of streptococcal (75%) isolates in community-acquired NSA is even more pronounced.

Entities:  

Mesh:

Year:  1983        PMID: 6363350

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  3 in total

1.  Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis.

Authors:  L Tissi; M Puliti; R Barluzzi; G Orefici; C von Hunolstein; F Bistoni
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Group B Streptococci Induce Proinflammatory Responses via a Protein Kinase D1-Dependent Pathway.

Authors:  Kirtikumar Upadhyay; Jeoung-Eun Park; Tae Won Yoon; Priyanka Halder; Young-In Kim; Victoria Metcalfe; Ajay J Talati; B Keith English; Ae-Kyung Yi
Journal:  J Immunol       Date:  2017-05-01       Impact factor: 5.422

3.  In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G.

Authors:  L Tissi; C von Hunolstein; P Mosci; C Campanelli; F Bistoni; G Orefici
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.